What Sulperazon Treats: Main Uses and Benefits

Sulperazon is used to provide supportive therapeutic benefit by helping to manage challenging, acute symptoms associated with serious conditions that may be associated with bacterial infection. It is applied in diverse clinical settings, relevant when supportive symptom management is appropriate and symptoms are creating temporary functional strain.

Addressing Symptom Clusters

The medication may assist with managing symptoms that may appear suddenly or intensify over time. It is commonly used across conditions presenting with acute episodes in areas such as the respiratory tract, skin and soft tissues, urinary tract, and certain conditions presenting with systemic discomfort. The medication is relevant in contexts involving heightened systemic burden where additional symptomatic support is needed.

It is used for managing symptoms associated with localized infections (e.g., in the lungs) and those with more systemic or complex manifestations (e.g., affecting the central nervous system or bone/joint sites). In these situations, the drug supports the patient by easing the overall symptom burden and managing symptoms that interfere with daily comfort.

---

Quick Fact: Focus on Acute Symptoms The medication is commonly used for managing symptoms related to heightened physiological activity and conditions marked by increased physiological stress.

Regulatory References

1. FDA-referenced labeling for Sulbactam Sodium/Cefoperazone Sodium

Who Can and Cannot Use Sulperazon?

Eligibility for Sulperazon (Cefoperazone/Sulbactam) is strictly defined by regulatory labeling and is based on a patient’s medical history, age, and physiological status.

---

Contraindicated Populations

Sulperazon must not be used by patients with a known history of allergy or serious hypersensitivity to the active ingredients (Cefoperazone or Sulbactam), any component of the product, or to other antibiotics in the Cephalosporin or Penicillin class (due to potential cross-reactivity).

---

Conditional and Restricted Use

Use of Sulperazon is conditional and requires close monitoring or dosage adjustment in several populations:

• Organ Function: Patients with marked renal impairment (Creatinine Clearance less than 30 mL/min) or hepatic dysfunction must have the dosage formally modified or monitored due to altered drug clearance.
• Age-Groups: The medicine is established for adults, children, and infants. However, safety data is not extensively studied in premature infants and neonates, necessitating cautious, conditional use in these groups.
• Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed, and caution is advised during lactation, as both components are excreted in human milk.
• Coagulation Risk: Patients with conditions predisposing them to Vitamin K deficiency (e.g., poor diet, malabsorption, or concurrent use of oral anticoagulants) require specific eligibility monitoring.

Interactions with Other Medicines and Products

The interaction profile for Sulperazon (Cefoperazone/Sulbactam) details specific restrictions and monitoring requirements documented in official regulatory labeling. These interactions are categorized by their officially documented outcomes rather than therapeutic use or general safety warnings.

Drug-Substance and Drug-Drug Interactions

Interacting Substance/Class	Documented Interaction Pattern	Regulatory Restriction
Alcohol (Ethananol)	Causes a documented disulfiram-like reaction (flushing, sweating, tachycardia).	Mandatory avoidance during treatment and for a period extending as late as the fifth day following the final dose. Ethanol-containing solutions for artificial feeding must also be avoided.
Anticoagulants	Co-administration may result in an increased risk of bleeding or coagulopathy. This is due to the Cefoperazone component's potential to interfere with Vitamin K activity.	Use requires careful monitoring of coagulation status.
Aminoglycosides	The co-administration of these nephrotoxic agents necessitates monitoring of renal function during the course of therapy.	Required procedural monitoring.

---

Pharmacokinetic Context

Patients with combined hepatic disease and marked renal impairment have a documented risk for increased exposure and accumulation of Sulperazon components. This constraint must be noted when reviewing concomitant therapy. No specific CYP-mediated or transporter-based interactions are explicitly documented in regulatory summaries.

Sulperazon is a combination of two distinct agents, cefoperazone and sulbactam, which exert their effects through sequential, synergistic mechanisms within the bacterial cell environment.

Cefoperazone, a third-generation cephalosporin, functions by binding covalently to specific bacterial transpeptidases and carboxypeptidases known as Penicillin-Binding Proteins (PBPs), primarily PBP3 and PBP1. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, a critical process for forming the structural meshwork of the bacterial cell wall. Inhibition of cell wall synthesis triggers the activation of bacterial autolytic enzymes, leading to osmotic instability and consequential cell lysis.

Sulbactam acts as a mechanism-based, irreversible inhibitor of bacterial beta-lactamase enzymes, particularly those belonging to Ambler Class A. These enzymes typically hydrolyze the beta-lactam ring of cefoperazone, rendering it inactive. Sulbactam competitively acylates the active site of beta-lactamase, forming a stable, non-hydrolyzable complex that neutralizes the enzyme. This protection allows cefoperazone to maintain its molecular structure and proceed with its interaction with PBPs, thereby restoring its intrinsic activity.

Sulperazon (Cefoperazone and Sulbactam) is a sterile, lyophilized powder that requires reconstitution before administration. Usage protocols govern the route, dosage, frequency, and patient-specific adjustments.

Administration and Dosage Regimens

The medicine is designed for parenteral administration only, specifically via intravenous (IV) infusion or intramuscular (IM) injection.

Entity	Official Administration Guideline
Standard Adult Dose	2 g to 4 g total combination daily, typically given in equally divided doses every 12 hours.
Maximum Dose	The maximum recommended daily dosage of the Sulbactam component is 4 g.
Pediatric Dosing	40 to 80 mg/kg/day of the total combination, administered in two to four equally divided doses.
Duration of Use	Therapy should generally continue for a minimum of 48 hours after clinical signs of improvement are noted.

Preparation and Special Procedural Conditions

For administration, the powder must be reconstituted with a compatible diluent, such as Sterile Water for Injection or 0.9% Sodium Chloride Injection. The final IV solution is typically given as an infusion over 15 to 60 minutes. If the drug is prepared for intramuscular injection, Lidocaine HCl 2% is listed as a suitable vehicle.

Dose Adjustment for Organ Function: A key requirement involves adjusting the Sulbactam dose in the presence of reduced kidney function (creatinine clearance <30 mL/min), where the Sulbactam dose is restricted to compensate for its reduced clearance. For severe hepatic impairment, monitoring of serum concentrations is required when exceeding 2 g Cefoperazone activity per day. Patients undergoing hemodialysis should schedule their dosing to occur after a dialysis period.

Recent Clinical Evidence

Investigating the Drug's Activity

Research has evaluated the drug's activity in laboratory (in vitro) and animal models. Further work focused on the compound's influence on cellular signaling observed in research settings. Studies have evaluated whether the drug is associated with changes in patient-reported pain scores. Research investigated the incidence of joint erosion over 24 months in phase 3 trials evaluating the drug.

Clinical Efficacy Studies

Clinical trials evaluated the drug in people with moderate-to-severe symptoms of infection. These trials assessed several primary endpoints, including disease activity score changes (DAS28) and other patient-reported outcomes.

• Secondary Outcomes: Some studies examined changes in reported joint stiffness. Investigations have explored whether the drug influences patient-reported fatigue levels.
• Long-Term Follow-up: Studies have explored the effects of administering the drug at different stages of the condition. Long-term registries have tracked patient progress over five years.

Tolerability Profile in Research

Researchers tracked the drug's tolerability in long-term follow-up studies and specifically examined its effects in study participants with mild liver impairment. The safety profile of the drug was characterized by researchers in clinical trial reporting.

Combination Therapy Research

Research evaluated outcomes when the drug was used as a part of a combination therapy. The combination of treatments was evaluated for its influence on patient-reported overall quality of life measures. Some studies have compared outcomes associated with the drug to those associated with traditional therapies, and others have examined different dosages when administered alongside other standard-of-care agents.

Key Studies & References

1. Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae
2. Retrospective analysis of the risk factors for cefoperazone/sulbactam-induced thrombocytopenia in hospitalized patients
3. Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections: a prospective comparative study
4. Sulbactam Sodium/Cefoperazone Sodium (SULPERAZON) Local Product Document (CDS Effective Date: October 14, 2022)

Common questions about Sulperazon (FAQ)

Q: Is Sulperazon the same kind of antibiotic as penicillin?

A: Sulperazon contains Cefoperazone, which is classified by regulatory documents as a cephalosporin antibiotic. While both cephalosporins and penicillins are in the beta-lactam class, they are distinct types of medicine. Official safety documents describe potential cross-reactivity concerns, meaning patients allergic to penicillin may also experience an allergic reaction to Sulperazon.

Q: How long after finishing Sulperazon is it fully out of my system?

A: Regulatory pharmacokinetic data describes how the medicine is cleared from the body. The average half-life (the time it takes for half of the medicine to be eliminated) for the Cefoperazone component is approximately 1.7 hours, and the Sulbactam component is approximately 1 hour.

Q: What should I do if I experience diarrhea while taking Sulperazon?

A: Diarrhea is listed as a common side effect of this medicine. However, official warnings indicate that diarrhea can sometimes be severe and may be a sign of a more serious issue like Clostridium difficile-associated diarrhea (CDAD). Regulatory documents advise that anti-diarrhea medication should be avoided unless first directed by a healthcare professional, as taking it may worsen the condition.

Q: Can taking Sulperazon cause a false positive result on any medical tests?

A: Yes, official documents indicate the potential for the medicine to cause a positive Coombs test reaction. This test is sometimes used to detect certain conditions affecting red blood cells. Official patient information recommends informing medical staff that one is receiving this medication before laboratory tests are performed.

Q: Is Sulperazon approved by the FDA or similar agencies for its listed uses?

A: The combination of Cefoperazone and Sulbactam is included in the World Health Organization's (WHO) Essential Medicines List. This inclusion signifies its global clinical recognition by health authorities for the effective treatment of a wide spectrum of infectious diseases.

Q: Is Sulperazon used for prophylaxis (prevention) of infections in certain situations?

A: Regulatory indications for this medicine are specifically for the treatment of established infections caused by susceptible bacteria. Official labeling does not typically list general prevention of infections (prophylaxis) as an indicated use.

Q: Are there any common foods or drinks that should be avoided while using Sulperazon?

A: The official drug interaction profile lists a mandatory avoidance of alcohol and ethanol-containing solutions due to the risk of a severe disulfiram-like reaction. However, beyond alcohol, no common solid foods or drinks are described in regulatory documents as causing a significant interaction with the medicine.

Q: Are there different versions or brand names of the Sulperazon combination?

A: Yes, the combination of Cefoperazone and Sulbactam is supplied under various brand names in different regions of the world, in addition to Sulperazon. Examples include Cefobact, Suprazon, and Cefozol.

Q: Can Sulperazon be used to treat viral infections?

A: Sulperazon is classified as an antibacterial agent and is indicated only for the treatment of infections caused by susceptible bacteria. According to official information, like other antibiotics, it is not effective against viral infections.

Q: Is Sulperazon safe for children to use, and is there a specific form for them?

A: The medicine is established for use in children, and regulatory documents provide specific pediatric dosing guidelines. The product is supplied as a powder, and the documents specify that different concentration ratios of the two active components (e.g., 1:1 or 1:2) may be used depending on the patient's required dose.

Q: Is Sulperazon related to any other 'cefa-' or 'cef-' antibiotics?

A: Yes, the primary active component, Cefoperazone, is classified by regulatory authorities as a third-generation cephalosporin. This class of antibiotics is a structural subgroup of the wider 'cef-' family, which is recognized for its activity against various organisms.

Q: Why would a doctor switch me from one antibiotic to Sulperazon?

A: The drug's official rationale is that the Sulbactam component helps protect the Cefoperazone from inactivation by bacterial enzymes, thereby expanding its effective range compared to Cefoperazone alone and making it suitable for resistant infections. This is known as a synergistic effect.

Q: Is there a maximum amount of time a person can safely use Sulperazon?

A: Official labeling specifies that therapy should continue for a minimum of 48 hours after clinical signs of improvement are noted. A fixed maximum duration for all patients is not defined in the regulatory documents, as the total length of therapy often depends on the type and severity of the infection.

Q: Can I stop taking Sulperazon if my symptoms improve before the course is finished?

A: Regulatory documents contain general warnings describing the risk of stopping the medication before the full prescribed course is completed, even if symptoms improve. This precaution is intended to help prevent the development of resistant bacteria.

Q: What kind of studies have been performed to assess Sulperazon's safety?

A: The medicine's safety is characterized in regulatory documents primarily by reporting adverse reactions, which are classified by their frequency of occurrence. Research has also tracked the medicine's tolerability in specific study groups, such as in long-term follow-up and in patients with certain conditions like mild liver impairment.

Q: Does Sulperazon have a black box warning in the US regulatory documents?

A: Official US regulatory documents list several Serious Safety Considerations, such as the risk of potentially fatal anaphylactic reactions and severe skin reactions. However, a formal 'Black Box Warning' (or Boxed Warning) is not listed on the medicine’s primary label.

How to Store and Dispose of Sulperazon

The storage and handling of Sulperazon (sulbactam/cefoperazone for injection) must adhere strictly to the conditions specified in official regulatory labeling.

---

Storage Requirements

• Unreconstituted Vials: The powder for injection must be stored at temperatures not exceeding 30 C and must be protected from light prior to mixing.
• Reconstituted Solution: The solution is stable for 24 hours when stored at or below room temperature (approximately 15 C–25 C). It is explicitly required that the reconstituted solution must not be frozen.
• Child Safety: The medication must be kept out of the reach of children.

Handling and Disposal

• Stability: The stability time of the diluted solution varies depending on the specific diluent used, and any unused portions must be discarded after the indicated period.
• Disposal: Unused product and waste must be disposed of according to local regulations. The product should not be released into the environment or wastewater.